In accordance with our findings, a recent report demonstrates that oncogenic KRAS requires EGF stimulation for enhanced activity in pancreatic cancer cells: EGF induced a prolonged activity of oncogenic KRAS, whereas only transient effects are seen in cells with wild type KRAS [15]. The gene discussed is KRAS; the disease is pancreatic neoplasm.